Prevalence of Risk Factors for Liver Disease in a Random Population Sample in Southern Germany

Huetter, Marie-Luise; Fuchs, Michael; Hänle, M; Mason, Richard; Akinli, A. S.; Imhof, Armin; Kratzer, Wolfgang; Lorenz, Reinhard

doi:10.1055/s-0034-1366017

Cited by 3 publications

(3 citation statements)

References 17 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nationwide cost reduction by PAGE-B adapted HCC screening was derived from population-based source data (additional Table 2), reporting cHB prevalence rates of 0.3% up to 0.7% in Germany [18][19][20][21]. The number of eligible patients was further adjusted by the rate (85-93%) of Caucasian HBsAg positive patients (Table 1) [22].…”

Section: Cost Reduction By Page-b Score Adapted Hcc Screeningmentioning

confidence: 99%

Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B

Sprinzl

Feist

Koch

et al. 2021

BMC Health Serv Res

View full text Add to dashboard Cite

Background The PAGE-B score (Platelet Age GEnder–HBV) selects chronic hepatitis B (cHB) patients showing no relevant 5-year risk for hepatocellular carcinoma (HCC). We, therefore, explored potential cost reduction following the introduction of a PAGE-B tailored ultrasound screening in a single center cohort of cHB patients receiving stable antiviral therapy. Methods cHB patients attending throughout the year 2018 were documented. Patients eligible for PAGE-B score were classified into high (≥18 points), intermediate (10–17 points) and low (≤9 points) HCC risk groups. Patients of the low HCC risk group could postpone HCC screening to reduce HCC screening expenses. Full costs for hepatic ultrasound were assessed. Results Throughout the year cHB patients (n = 607) attended our clinic, which included PAGE-B eligible patients (n = 227, 37.4%) of whom n = 94 (15.8%) were allocated to the low HCC risk group. Sonographic HCC screening during a median exam time of 12.4 min (IQR 9.2–17.2) resulted in total costs of 22.82 Euro/exam. Additional opportunistic expenses caused by patient’s lost earnings or productivity were 15.6–17.5 €/exam and 26.7 €/exam, respectively. Following a PAGE-B tailored HCC screening at our institution annual full costs for cHB patients could be reduced by 15.51%, which equals a cost reduction by 1.91% for our total sonography unit. In comparison, 1.35% up to 7.65% of HBV-infected patients of Caucasian descent could postpone HCC screening according to population-based estimates from Germany. Conclusions PAGE-B risk score adapted screening for HCC is an efficient and cost neutral tool to reduce costs for sonography in Caucasian patients with chronic hepatitis B receiving antiviral treatment.

show abstract

Section: Cost Reduction By Page-b Score Adapted Hcc Screeningmentioning

confidence: 99%

Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B

Sprinzl

Feist

Koch

et al. 2021

BMC Health Serv Res

View full text Add to dashboard Cite

show abstract

“…The PAGE-B score was calculated based on age, gender and thrombocyte count. PAGE-B strata were classi ed into high (≥ 18 points), intermediate (10)(11)(12)(13)(14)(15)(16)(17) points) and low (≤ 9 points) HCC risk groups (additional Table 1) [8]. Patients eligible for PAGE-B score assessment had to receive effective antiviral therapy with second generation NA including entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF) for at least one year.…”

Section: Data Acquisition and Patient Selectionmentioning

confidence: 99%

Section: Full Cost Calculation Of Sonographic Hcc Screeningmentioning

confidence: 99%

Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B

Sprinzl

Feist

Koch

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The PAGE-B score (Platelet Age GEnder–HBV) selects chronic hepatitis B (cHB) patients showing no relevant 5-year risk for hepatocellular carcinoma (HCC). We, therefore, explored potential cost reduction following the introduction of a PAGE-B tailored ultrasound screening in a cohort of cHB patients receiving stable antiviral therapy.Methods: cHB patients attending throughout the year 2018 were documented. Patients eligible for PAGE-B score were classified into high (≥18 points), intermediate (10-17 points) and low (≤9 points) HCC risk groups. Patients of the low HCC risk group could postpone HCC screening to reduce HCC screening expenses. Full costs for hepatic ultrasound were assessed. Results: Throughout the year cHB patients (n=607) attended our clinic, which included PAGE-B eligible patients (n=227, 37.4%) of whom n=94 (15.8%) were allocated to the low HCC risk group. Sonographic HCC screening during a median exam time of 12.4 minutes (IQR 9.2-17.2) resulted in total costs of 22.82 Euro/exam. Additional opportunistic expenses caused by patient´s lost earnings or productivity were 15.6-17.5 €/exam and 26.7 €/exam, respectively. Following a PAGE-B tailored HCC screening at our institution annual costs for cHB patients could be reduced by 15.51%, which equals a cost reduction by 1.91% for our total sonography unit. In comparison, 1.59% up to 3.85% of HBV-infected patients could postpone HCC screening according to population-based estimates from Germany.Conclusions: PAGE-B risk score adapted screening for HCC is an efficient and cost neutral tool to reduce costs for sonography in patients with chronic hepatitis B receiving antiviral treatment.

show abstract

Epidemiology and Risk Factors for Alcoholic Liver Disease

Lazo

Mitchell

2016

Alcoholic and Non-Alcoholic Fatty Liver Disease

View full text Add to dashboard Cite

Prevalence of Risk Factors for Liver Disease in a Random Population Sample in Southern Germany

Abstract: Many cases of chronic liver disease could be prevented by healthy nutrition, optimized medical treatment of associated disorders, and prevention strategies such as routine vaccination, in particular, against hepatitis B virus (HBV).

Cited by 3 publications

References 17 publications

Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B

Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B

Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B

Epidemiology and Risk Factors for Alcoholic Liver Disease

Contact Info

Product

Resources

About